{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T20:54:16Z","timestamp":1771102456249,"version":"3.50.1"},"reference-count":45,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA174844"],"award-info":[{"award-number":["R01 CA174844"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA229961"],"award-info":[{"award-number":["R21 CA229961"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1 TR002551"],"award-info":[{"award-number":["TL1 TR002551"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002550"],"award-info":[{"award-number":["UL1 TR002550"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,10,25]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite numerous therapeutic options, safe and curative therapy is unavailable for most patients with chronic lymphocytic leukemia (CLL). A drawback of current therapies such as the anti-CD20 monoclonal antibody (mAb) rituximab is the elimination of all healthy B cells, resulting in impaired humoral immunity. We previously reported the identification of a patient-derived, CLL-binding mAb, JML-1, and identified sialic acid-binding immunoglobulin-like lectin-6 (Siglec-6) as the target of JML-1. Although little is known about Siglec-6, it appears to be an attractive target for cancer immunotherapy due to its absence on most healthy cells and tissues.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used a target-specific approach to mine for additional patient-derived anti-Siglec-6 mAbs. To assess the therapeutic utility of targeting Siglec-6 in the context of CLL, T cell-recruiting bispecific antibodies (T-biAbs) that bind to Siglec-6 and CD3 were engineered into single-chain variable fragment\u2013Fc and dual-affinity retargeting (DART)\u2013Fc constructs. T-biAbs were evaluated for their activity in vitro, ex vivo, and in vivo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We discovered the anti-Siglec-6 mAbs RC-1 and RC-2, which bind with higher affinity than JML-1 yet maintain similar specificity. Both JML-1 and RC-1 T-biAbs were effective at activating T cells and killing Siglec-6<jats:sup>+<\/jats:sup> target cells. The RC-1 clone in the DART\u2013Fc format was the most potent T-biAb tested and was the only anti-Siglec-6 T-biAb that eliminated Siglec-6<jats:sup>+<\/jats:sup> primary CLL cells via autologous T cells at pathological T-to-CLL cell ratios. Tested at healthy T-to-B cell ratios, it also eliminated a Siglec-6<jats:sup>+<\/jats:sup> fraction of primary B cells from healthy donors. The subpicomolar potency of the DART\u2013Fc format was attributed to the reduction in the length and flexibility of the cytolytic synapse. Furthermore, the RC-1 T-biAb was effective at clearing MEC1 CLL cells in vivo and demonstrated a circulatory half-life of over 7\u2009days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Siglec-6-targeting T-biAbs are highly potent and specific for eliminating Siglec-6<jats:sup>+<\/jats:sup> leukemic and healthy B cells while sparing Siglec-6<jats:sup>\u2212<\/jats:sup> healthy B cells, suggesting a unique treatment strategy for CLL with diminished suppression of humoral immunity. Our data corroborate reports that T-biAb efficacy is dependent on synapse geometry and reveal that synapse architecture can be tuned via antibody engineering. Our fully human anti-Siglec-6 antibodies and T-biAbs have potential for cancer immunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00923507\">NCT00923507<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-004850","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T10:00:51Z","timestamp":1669629651000},"page":"e004850","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00923507","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00923507","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01500733","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02337829","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00923507","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01500733","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02337829","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-4300","authenticated-orcid":false,"given":"Matthew G","family":"Cyr","sequence":"first","affiliation":[{"name":"Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"},{"name":"Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0733-3046","authenticated-orcid":false,"given":"Maissa","family":"Mhibik","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpeng","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-1337","authenticated-orcid":false,"given":"Haiyong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika M","family":"Gaglione","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Eik","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Herrick","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Venables","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J","family":"Novick","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-7767","authenticated-orcid":false,"given":"Valentine V","family":"Courouble","sequence":"additional","affiliation":[{"name":"Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, Florida, USA"},{"name":"Department of Molecular Medicine, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick R","family":"Griffin","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-3454","authenticated-orcid":false,"given":"Christoph","family":"Rader","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA"},{"name":"Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"2025100307555373000_10.11.e004850.1","unstructured":"SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia. Surveillance, Epidemiology, and End Results Program 2018. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html"},{"key":"2025100307555373000_10.11.e004850.2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102468","article-title":"Current treatment options in CLL","volume":"13","author":"Bewarder","year":"2021","journal-title":"Cancers"},{"key":"2025100307555373000_10.11.e004850.3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101189"},{"key":"2025100307555373000_10.11.e004850.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294"},{"key":"2025100307555373000_10.11.e004850.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-585075"},{"key":"2025100307555373000_10.11.e004850.6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222588"},{"key":"2025100307555373000_10.11.e004850.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006965"},{"key":"2025100307555373000_10.11.e004850.8","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"2025100307555373000_10.11.e004850.9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11899-018-0476-4","article-title":"Hematopoietic stem cell transplantation in the era of engineered cell therapy","volume":"13","author":"Appelbaum","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"2025100307555373000_10.11.e004850.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)90004-2"},{"key":"2025100307555373000_10.11.e004850.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222786"},{"key":"2025100307555373000_10.11.e004850.12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0102"},{"key":"2025100307555373000_10.11.e004850.13","unstructured":"Siglec-6 . The human protein atlas, 2021. Available: https:\/\/www.proteinatlas.org\/ENSG00000105492-SIGLEC6"},{"key":"2025100307555373000_10.11.e004850.14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","article-title":"Siglecs as immune cell checkpoints in disease","volume":"38","author":"Duan","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"2025100307555373000_10.11.e004850.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45685"},{"key":"2025100307555373000_10.11.e004850.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756"},{"key":"2025100307555373000_10.11.e004850.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-830992"},{"key":"2025100307555373000_10.11.e004850.18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood"},{"key":"2025100307555373000_10.11.e004850.19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton's tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front Immunol"},{"key":"2025100307555373000_10.11.e004850.20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025100307555373000_10.11.e004850.21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"2025100307555373000_10.11.e004850.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.11.021"},{"key":"2025100307555373000_10.11.e004850.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719905115"},{"key":"2025100307555373000_10.11.e004850.24","doi-asserted-by":"crossref","first-page":"12178","DOI":"10.1002\/anie.202005432","article-title":"Chemically programmable and switchable CAR-T therapy","volume":"59","author":"Qi","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"2025100307555373000_10.11.e004850.25","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1038\/s41375-021-01188-3","article-title":"Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia","volume":"35","author":"Kovalovsky","year":"2021","journal-title":"Leukemia"},{"key":"2025100307555373000_10.11.e004850.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2014.08.007"},{"key":"2025100307555373000_10.11.e004850.27","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"2025100307555373000_10.11.e004850.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4576"},{"key":"2025100307555373000_10.11.e004850.29","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"2025100307555373000_10.11.e004850.30","first-page":"748-751","article-title":"Siglec-6 as a new potential immune checkpoint for bladder cancer patients","volume":"8","author":"Benmerzoug","year":"2022","journal-title":"Eur Urol Focus"},{"key":"2025100307555373000_10.11.e004850.31","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0798-677"},{"key":"2025100307555373000_10.11.e004850.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0844-y"},{"key":"2025100307555373000_10.11.e004850.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2010.04.001"},{"key":"2025100307555373000_10.11.e004850.34","doi-asserted-by":"crossref","DOI":"10.3390\/antib5010006","article-title":"Development of PF-06671008, a highly potent anti-P-cadherin\/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer","volume":"5","author":"Root","year":"2016","journal-title":"Antibodies"},{"key":"2025100307555373000_10.11.e004850.35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-306449"},{"key":"2025100307555373000_10.11.e004850.36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax8861"},{"key":"2025100307555373000_10.11.e004850.37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35017"},{"key":"2025100307555373000_10.11.e004850.38","doi-asserted-by":"publisher","DOI":"10.1021\/ja311795d"},{"key":"2025100307555373000_10.11.e004850.39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax1315"},{"key":"2025100307555373000_10.11.e004850.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-709519"},{"key":"2025100307555373000_10.11.e004850.41","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00360"},{"key":"2025100307555373000_10.11.e004850.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.03.003"},{"key":"2025100307555373000_10.11.e004850.43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.233841"},{"key":"2025100307555373000_10.11.e004850.44","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0379"},{"key":"2025100307555373000_10.11.e004850.45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02138","article-title":"Functional inhibitory Siglec-6 is upregulated in human colorectal cancer-associated mast cells","volume":"9","author":"Yu","year":"2018","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-004850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:55:59Z","timestamp":1759503359000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-004850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,28]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/jitc-2022-004850"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-004850","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}